Recovery and Purification: Innovations to Simplify Downstream Bioprocessing

摘要

Adownstream process that leverages the advantages of innovative technologies such as disposables, in-line monitoring, and high-throughput systems as well as the robust methods for its harvest and purification steps can signficantly improve in a company's time (and cost) to clinic or commercialization. The 2011 BioProcess International Conference and Exhibition provides forward-thinking presentations that can help you define, characterize, and simplify your downstream design space. Many biomanufacturers have already experienced the advantages of high-throughput systems and platform processes in their efforts to accelerate process development and reduce time to clinical trials. The preponderance of biologies on the market today are monoclonoal antibodies (MAbs), which have a well-established, well-characterized manufacturing process. Although many MAbs can undergo platform processes, others cannot and so require further development.